Navigation Links
MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy
Date:2/9/2017

CHICAGO, Feb. 9, 2017 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association today welcomed news of the U.S. Food and Drug Administration's decision to grant approval for deflazacort (brand name Emflaza), under development by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.

Approval of the drug, which is labeled for use by people 5 years or older with Duchenne muscular dystrophy (DMD), regardless of genetic mutation, is an unprecedented third drug in six months approved for diseases included in MDA's program. It marks a solid step forward in the development of therapies for DMD and related neuromuscular diseases, and represents continued success for MDA and the entire DMD community.

The Muscular Dystrophy Association today welcomed news of the U.S. Food and Drug Administration's decision to grant approval for deflazacort (brand name Emflaza), under development by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.
The Muscular Dystrophy Association today welcomed news of the U.S. Food and Drug Administration's decision to grant approval for deflazacort (brand name Emflaza), under development by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.

"Today we celebrate FDA approval of Emflaza as a treatment option for kids and adults living with Duchenne muscular dystrophy," said MDA President and CEO Steven M. Derks. "This approval follows decades of MDA research — including early-stage development and testing of Emflaza in DMD patients — that was made possible by the hard work, dedication and unwavering commitment of our donors and sponsors. Drugs like Emflaza aren't developed in silos, but rather through the combined efforts of biotechs and drug companies, patient organizations like MDA, corporate partners and donors, and the families who are there every step of the way to see it through. We are grateful to be part of such a welcome new development in the DMD landscape — and, more importantly, to belong to such a giving and dedicated community."

Marathon Pharmaceuticals plans to make its commercial supply of Emflaza, in both tablet and oral suspension formulations, available as quickly as possible. An expanded access program (EAP) for the drug, called AccessDMD, will end soon, but Marathon has committed to ensuring continued product supply to patients while they transition to the commercial supply.

Emflaza, a corticosteroid, works as an anti-inflammatory and immunosuppressant. It has been shown to slow the loss of muscle strength and function, preserve cardiac and respiratory function, and reduce the incidence of curvature of the spine (scoliosis) in people with DMD. Importantly, the unwanted side effects often experienced with corticosteroids, such as weight gain, loss of bone mass, glucose intolerance (diabetes) and behavioral issues, may be less severe with Emflaza as compared to other steroids.

Corticosteroids are commonly used to treat DMD across the world. This is the first FDA approval of any corticosteroid to treat DMD and the first approval of Emflaza for any use in the United States.

"Emflaza has shown meaningful benefits for patients living with DMD and has the potential to delay disease progression," MDA Executive Vice President and Chief Medical and Scientific Officer Valerie A. Cwik, M.D., said. "With the FDA approval of Emflaza, we now have a treatment option for kids and adults with Duchenne, which is a major advance for the community. As a physician, I participated in a clinical trial of Emflaza and have a keen awareness about what the approval of this drug means for patients and families."

MDA has a long history of supporting research and clinical study into the effects of corticosteroids, including Emflaza, in DMD, and has invested more than $1.5 million in studies to determine drug effects, mechanism of action, side effects and best dosing regimen. To date, MDA has funded more than $200 million in DMD research.

FDA approval of Emflaza marks a third major proof point of MDA's research program in recent months. Exondys 51 in September 2016 became the first disease-modifying drug approved by the FDA to treat DMD. The FDA in December approved Spinraza for the treatment of spinal muscular atrophy, another of the diseases in MDA's program. The approvals for these drugs mark a significant step forward in the development of therapies for neuromuscular diseases.

To learn more watch FDA Approves Deflazacort for Duchenne Muscular Dystrophy.

About MDA
MDA is leading the fight to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. We use our collective strength to help kids and adults live longer and grow stronger by finding research breakthroughs across diseases; caring for individuals from day one; and empowering families with services and support in hometowns across America. Learn how you can fund cures, find care and champion the cause at mda.org.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mda-celebrates-news-of-fda-approval-of-emflaza-for-treatment-of-duchenne-muscular-dystrophy-300405440.html


'/>"/>
SOURCE Muscular Dystrophy Association
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. JDRF Eastern Pennsylvania Chapter Celebrates a $110K Gift Spearheaded by the ONeil Family Celebrating the Approval of the First Commercial Artificial Pancreas
2. FDA Voice Blog: FDAs Naloxone App Prize Competition Celebrates Innovation In Search of Technological Solutions to the Opioid Epidemic
3. Canon U.S.A. Celebrates the 40th Anniversary of the Worlds First Non-Mydriatic Camera
4. Parenteral Drug Association Celebrates 70 Years of Connecting People, Science and Regulation
5. Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
6. Worlds Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart
7. PPA connects nearly 10 million people; Celebrates 11th anniversary and launches mobile app
8. Medical Match Makers Celebrates 12 Successful Years
9. Elsevier Celebrates 100 Years of Medical Clinics
10. CSI Celebrates 38 Years In The Medical Health Kiosk Business And Surpasses One Billion Tests On Its Health System Kiosks
11. Diplomat Celebrates Multiple Sclerosis Week with National Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):